See more : Shimizu Corporation (SHMUF) Income Statement Analysis – Financial Results
Complete financial analysis of Sol-Gel Technologies Ltd. (SLGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sol-Gel Technologies Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- CSB Bank Limited (CSBBANK.BO) Income Statement Analysis – Financial Results
- ShineMore Technology Materials Co., Ltd. (8291.TWO) Income Statement Analysis – Financial Results
- Black Diamond Therapeutics, Inc. (BDTX) Income Statement Analysis – Financial Results
- China New Higher Education Group Limited (2001.HK) Income Statement Analysis – Financial Results
- Exmar NV (EXM.BR) Income Statement Analysis – Financial Results
Sol-Gel Technologies Ltd. (SLGL)
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.55M | 3.88M | 31.27M | 8.77M | 22.90M | 129.00K | 174.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 300.00K | 359.00K | 300.00K | 0.00 |
| Gross Profit | -21.99M | -8.80M | 10.89M | -19.14M | -17.67M | -28.02M | -126.00K | -359.00K | -300.00K | 0.00 |
| Gross Profit Ratio | -1,414.86% | -226.60% | 34.83% | -218.24% | -77.17% | -21,718.60% | -72.41% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 25.81M | 17.02M | 7.18M | 2.93M |
| General & Administrative | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Other Expenses | -55.00K | 0.00 | -524.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Cost & Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Interest Income | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 40.00K |
| Interest Expense | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 342.00K | 562.00K | 880.00K | 946.00K | 887.00K | 762.00K | 300.00K | 359.00K | 300.00K | 225.00K |
| EBITDA | -28.96M | -15.68M | 3.84M | -29.29M | -25.06M | -32.76M | -31.16M | -20.40M | -9.35M | -4.58M |
| EBITDA Ratio | -1,863.77% | -403.86% | 9.48% | -344.69% | -109.43% | -25,394.57% | -17,909.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.31M | -16.24M | 2.08M | -30.23M | 25.95M | -33.52M | -31.63M | -20.76M | -9.65M | -4.81M |
| Operating Income Ratio | -1,885.78% | -418.34% | 6.66% | -344.69% | 113.30% | -25,985.27% | -18,179.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 1.32M | 65.00K | -15.00K | -13.00K | -40.00K |
| Income Before Tax | -27.24M | -14.92M | 3.22M | -29.29M | -24.58M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Income Before Tax Ratio | -1,752.77% | -384.32% | 10.30% | -333.94% | -107.30% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -1.14M | -1.89M | 33.00K | -1.32M | -65.00K | 15.00K | 13.00K | 0.00 |
| Net Income | -27.24M | -13.60M | 4.36M | -27.40M | -24.61M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Net Income Ratio | -1,752.77% | -350.30% | 13.94% | -312.40% | -107.44% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -0.59 | 0.19 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| EPS Diluted | -1.01 | -0.59 | 0.18 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| Weighted Avg Shares Out | 27.09M | 23.13M | 23.06M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
| Weighted Avg Shares Out (Dil) | 27.09M | 23.13M | 23.57M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
Sol-Gel: Slow And Steady Topical Technology
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
Source: https://incomestatements.info
Category: Stock Reports